Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma
Brief Summary: The purpose of this study is to assess peak FEV1 of two doses of QVM149 compared to a fixed-dose combination of salmeterol/fluticasone (50/500μg b.i.d.) and to characterize the respective 24 hour bronchodilator effect profiles in patients with asthma. Data from this study will complement lung function data obtained in the pivotal QVM149 phase 3 program by assessing the bronchodilatory effect of QVM149 at multiple time-points over an entire dosing interval of 24 hours.


Options:
A: Arm Label: Sequence 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Arm Label: Sequence 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: QVM149 150/50/80 μg o.d., Drug: QVM149 150/50/160 μg o.d., Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d. | Intervention Type: DRUG; Name: QVM149 150/50/80 μg o.d.; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6 | Intervention Type: DRUG; Name: QVM149 150/50/160 μg o.d.; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6 | Intervention Type: DRUG; Name: salmeterol/fluticasone FDC 50/500 μg b.i.d.; Assigned to Arm(s): Sequence 1, Sequence 2, Sequence 3, Sequence 4, Sequence 5, Sequence 6
B: Arm Label: Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/28.8/9.6 μg | Arm Label: BGF MDI 320/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: BFF MDI 320/9.6 μg | Arm Label: Symbicort®; Type: ACTIVE_COMPARATOR; Interventions: Drug: BFF pMDI 320/9 μg | Intervention Type: DRUG; Name: BGF MDI 320/28.8/9.6 μg; Assigned to Arm(s): Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF MDI 320/14.4/9.6 μg | Intervention Type: DRUG; Name: BFF MDI 320/9.6 μg; Assigned to Arm(s): Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg | Intervention Type: DRUG; Name: BFF pMDI 320/9 μg; Assigned to Arm(s): Symbicort®
C: Arm Label: FLAMBOYANT 125/12; Type: EXPERIMENTAL; Interventions: Drug: Flamboyant 125/12, Other: Budesonide/formoterol 200/6 placebo | Arm Label: Budesonide/formoterol 200/6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide/formoterol 200/6, Other: Flamboyant 125/12 Placebo | Intervention Type: DRUG; Name: Flamboyant 125/12; Assigned to Arm(s): FLAMBOYANT 125/12 | Intervention Type: DRUG; Name: Budesonide/formoterol 200/6; Assigned to Arm(s): Budesonide/formoterol 200/6 | Intervention Type: OTHER; Name: Flamboyant 125/12 Placebo; Assigned to Arm(s): Budesonide/formoterol 200/6 | Intervention Type: OTHER; Name: Budesonide/formoterol 200/6 placebo; Assigned to Arm(s): FLAMBOYANT 125/12
D: Arm Label: Foster® NEXThaler®; Type: EXPERIMENTAL; Interventions: Drug: Foster® NEXThaler® 100/6 µg/unit dose | Arm Label: Seretide® Accuhaler®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Seretide® Accuhaler® 250/50 µg/actuation | Intervention Type: DRUG; Name: Foster® NEXThaler® 100/6 µg/unit dose; Assigned to Arm(s): Foster® NEXThaler® | Intervention Type: DRUG; Name: Seretide® Accuhaler® 250/50 µg/actuation; Assigned to Arm(s): Seretide® Accuhaler®

Answer: A